Repligen (NASDAQ:RGEN – Free Report) had its price objective cut by Jefferies Financial Group from $145.00 to $135.00 in a report issued on Friday,Benzinga reports. They currently have a hold rating on the biotechnology company’s stock.
Several other brokerages also recently commented on RGEN. Barclays initiated coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price objective for the company. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Wells Fargo & Company lowered their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Finally, Stephens raised Repligen to an “overweight” rating and set a $160.00 price objective on the stock in a research report on Tuesday, July 22nd. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $166.67.
Get Repligen alerts:
View Our Latest Research Report on Repligen
Repligen Stock Performance
Repligen stock opened at $113.54 on Friday. The company has a market capitalization of $6.39 billion, a PE ratio of -454.14, a P/E/G ratio of 2.09 and a beta of 1.07. The firm has a fifty day simple moving average of $120.73 and a two-hundred day simple moving average of $127.58. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $102.96 and a twelve month high of $182.52.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts expect that Repligen will post 1.72 EPS for the current year.
Insiders Place Their Bets
In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the business’s stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.
Institutional Investors Weigh In On Repligen
A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD grew its holdings in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after purchasing an additional 400,970 shares during the period. Geneva Capital Management LLC grew its holdings in Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares during the period. Blue Whale Capital LLP purchased a new stake in Repligen in the second quarter worth about $35,782,000. Finally, Nuveen LLC purchased a new stake in shares of Repligen during the first quarter valued at approximately $35,536,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
About Repligen
(Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Five stocks we like better than Repligen
What Is WallStreetBets and What Stocks Are They Targeting?
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
How to Buy Cheap Stocks Step by Step
Football Season Is Here and DraftKings Stock Is Surging
How to Use High Beta Stocks to Maximize Your Investing Profits
RH Stock Slides After Mixed Earnings and Tariff Concerns